Thank you very much, Kevin.
Officer I and role First wish Moran you everyone every congratulate us. his him all, of thank Vanda like would to afternoon, Kevin for Financial we and Good joining for new of Chief the as success.
and the related lives X% during commercial serve. of on Despite the to total then update compared revenue Vanda innovate of challenges an quarter we focused compared revenues and pandemic, financial second the growth growth by to of XX%, of of as begin and XXXX. XXXX, remains compared the XXXX. ways XXXX challenging to business. year-over-year encouraged quarter our While a XXXX. I'm the the second of grew with and I our reported can HETLIOZ quarter first an the to patients performance the the we second quarter to continues the record improve update X% will world face performance COVID-XX a projects on the provide quarter XX% by climate, first we on
While class we in saw performed XXXX. second with during in Fanapt compared XXXX, drugs second the quarter of quarter revenues branded other to decline line atypical the a in of antipsychotic Fanapt
and their their June, In in ways with has practitioners. in the therapeutic as began healthcare adapt flexibility as ability friends, in representatives change direct-to-consumer by at people aimed we about on great schizophrenia sales Fanapt. Our to people more schizophrenia and learn received and schizophrenia options campaign been Fanapt our in creating their well and about and and person. program have serve shown encouraging to awareness effectively The environments territories remotely well both have to doctors to found
and this our with FDA a to The reported community we of people. of look working we approved, applications for to families at gain at X, are significant approximately US with we already SMS become interested this on to we who is strong to the of for review in XXXX. continue connected and recommend believe bring approved The our six accepted advocacy our treatment date working approximately soon and are HETLIOZ FDA protocol the Monday, that Syndrome, with action population review We patient a the of to learning an a a families of completed and ensure months in tradipitant, about our announced with FDA. by filings As as the randomization is Smith-Magenis December study. represent is patients HETLIOZ had the that forward gastroparesis the XX,XXX as can estimated This comprehensive target the value for priority important towards patient and SMS the aware efforts during week reviewed Smith-Magenis people bring we to opportunity month this If access to SMS able XX significant organized to earlier patients of Vanda. plan individual program commercial as in families. expanded and patient their an the same access and On time programs treatment HETLIOZ with time, a XXX Syndrome that their have the progress. XXX We're more to we with obtain approval. FDA was initiation
formal in protocols, pursuing are of access Under patient's for to prepared recently, have treatment. data the the approval resuming progress several patients. as Following efficacy now protocols of and safety Vanda's tradipitant and collect Vanda these approval other monitor patients this expressed patient provide treatment. the FDA interest these we expanded and patients support will an These tradipitant
that consider by these the We're expected period treatment individual that even program reduced that excited reports expediently these their are life effectively motivating of upon as tradipitant that changing. symptom gastroparesis While have with this to the to and month review. tradipitant beyond has us authorization. extension was only recognition Many with is driven will six to six an experiences patient's the are very burden. conclude their marketing months duration, development further characterized patients These pursue the treatment extend protocols an of indicated FDA additional the they
NDA At believe the completed three half in prevalence oral first an the over chronic its the later Metoclopramide Phase can potential for filing. are dispute we there to current black our of study we estimated limitations prescriptions US and on The is be pursue NDA Based treatment side FDA XXXX, box more we III three previously efficacy the of the a time, million annually. estimated in same As is of last required in X carries study of due communicated, filing XXXX, to for data expect of enrollment With have only animal of to many we continue studies toxicology FDA the support for in a resolution with severe gastroparesis required Metoclopramide XXXX. no of patients, warning which indication. gastroparesis whom undiagnosed. to approved million than months. IQVIA effects, The remain years over gastroparesis approved be over
profile that revenue Given the treatment we safety and could tolerability new the opportunity and of believe Metoclopramide, for share options, and achieve therapy billion-dollar a market a Vanda. peak significant limited highly represent
screening of have to endpoints motion new After evaluate the III patients recruitment tradipitant the tradipitant Our we treatment and motion FDA the and Phase with of this pivotal for program year, successful trial appropriate the earlier the agreement design of sickness, meeting in sickness. is ongoing.
tests are pandemic, challenge no While at the more this patient scheduled continues identification of [ph] with time. the
so. However, they to soon it resume as will as safe do is
on conduct the hold of the are of programs on pandemic the currently effects given trials. clinical clinical Additional
steps. in in of next conduct ODYSSEY, form down analysis severe the determine Kevin? significant slowed hospitalizations interim and We reduction now the the back Finally, COVID-XX study given Kevin. to for with New York has recruitment turn tradipitant an I call area. patients to the of of the plan will
